AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Jill Dolgin, PharmD, will deliver the keynote address at the virtual Gene Therapy Patient Engagement Summit on March 24, 2021. Dolgin will discuss the importance of a patient-centric approach in advancing gene therapy clinical programs. Emphasizing the significance of patient engagement in the clinical development process, Dolgin aims to translate patient experiences into better outcomes. AGTC is focused on developing genetic therapies for rare diseases, with ongoing trials in conditions like X-linked retinitis pigmentosa and achromatopsia.

-AGTC will highlight the value of the patient voice in gene therapy development-

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, will address the impact of a patient-centric approach on advancing gene therapy clinical programs at the virtual Gene Therapy Patient Engagement Summit on Wednesday, March 24 at 8:30 AM ET.

Dr. Dolgin will give the opening keynote address, setting the stage for the meeting with a high-level overview of the evolution of gene therapy and patient engagement, specifically addressing why patient engagement is critical to the cell and gene therapy clinical development process and how it differs from other sectors.

“Our commitment to patient and caregiver engagement provides a wealth of insight into life with a rare retinal disorder,” said Dr. Dolgin. “In gene therapy development, working closely with patients allows us to translate their personal journey into a better clinical experience and potentially increase our chances to provide patients an improvement in the clinical outcome. I look forward to joining patient advocacy leaders to discuss the best strategies for engaging our communities to ultimately bring these transformative treatments to patients more quickly and effectively.”

The event is taking place March 23-25, 2021. To learn more about the event and registration, please visit: https://genetherapy-patient-engagement.com/take-part/register/

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR Contacts:
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

What is the purpose of the Gene Therapy Patient Engagement Summit on March 24, 2021, related to AGTC?

The summit aims to highlight the role of patient engagement in advancing gene therapy clinical programs, featuring a keynote by Jill Dolgin from AGTC.

Who is Jill Dolgin and what will she address at the summit?

Jill Dolgin, PharmD, is the Executive Director of Global Patient Advocacy at AGTC, and she will address the impact of patient-centric approaches on gene therapy.

What clinical trials is AGTC currently conducting?

AGTC is conducting clinical trials for X-linked retinitis pigmentosa and achromatopsia.

Why is patient engagement important in gene therapy development for AGTC?

Patient engagement provides insights that can improve clinical experiences and outcomes in gene therapy development.

What is AGTC's focus in gene therapy?

AGTC focuses on developing therapies for rare and debilitating diseases, especially in ophthalmic and CNS disorders.